Research and Markets (http://www.researchandmarkets.com/research/44c77e/chronic_myelogenou) has announced the addition of Decision Resources, Inc.'s new report "Chronic Myelogenous Leukemia: New Targeted Therapies Take Aim at Gleevec" to their offering. [More]

Scientists have devised an innovative way to disarm a key protein considered to be "undruggable," meaning that all previous efforts to develop a drug against it have failed. Their discovery, published in the November 12 issue of Nature, lays the foundation for a new kind of therapy aimed directly at a critical human protein — one of a few thousand so-called transcription factors — that could someday be used to treat a variety of diseases, especially multiple types of cancer. [More]

The Leukemia & Lymphoma Society (LLS) will again be participating in Gap Inc.'s Give & Get program, which in its first two campaigns this past spring and summer, garnered more than $1 million to support LLS's blood cancer research funding and patient education and support services. [More]

Two genes, each one of which is known to cause cancer on its own, together can lead to aggressive leukaemia. This is the conclusion from new research carried out on gene-modified mice at the Sahlgrenska Academy at the University of Gothenburg, Sweden. The discovery has surprised scientists, and may lead to new treatments. [More]

Two genes, each one of which is known to cause cancer on its own, together can lead to aggressive leukaemia. This is the conclusion from new research carried out on gene-modified mice at the Sahlgrenska Academy at the University of Gothenburg, Sweden. The discovery has surprised scientists, and may lead to new treatments. [More]

The Multiple Myeloma Research Foundation (MMRF) raised over $1.8 million at its 13th annual Fall Gala held on Saturday evening in Greenwich, Conn. Funds raised at this premier fundraising event, attended by more than 1,000 guests, will support the MMRF’s efforts to accelerate the development of the next generation of treatments for patients with multiple myeloma, a rare and incurable blood cancer, and to find a cure for the disease. [More]

Results of a phase two clinical trial published October 5th in the Journal of Clinical Oncology show that adding continuous daily doses of a targeted drug called imatinib mesylate to regular chemotherapy more than doubled three-year survival rates for children with a high risk type of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). [More]

Joint Stock Company Human Stem Cell Institute” (“HSCI” or “the Company”), Russia’s leader in stem cell technology, today announced the preliminary price range for its initial public offering (“IPO”). [More]

Acute lymphatic leukemia is the most common form of blood cancer in children. Even though chemotherapy is improving, the cancer often returns. Johan Jansson's research at Kalmar University in Sweden shows that cancer cells that have been exposed to chemotherapy and survived are less vulnerable to chemotherapy, and more aggressive as well. But this research also yielded discoveries that should be able to enhance our treatment of the disease. [More]

The cure rates for many cancers have improved dramatically over the past decades, but the harsh reality is that too many cancer survivors suffer serious side-effects of their curative treatments. Toxic side-effects can occur months or years after the treatments are finished, sometimes as chronic conditions, sometimes life-threatening, but always unacceptably reducing a patient's quality of life. [More]

In many types of cancer, parts of the genetic material of tumor cells are switched off by chemical labels called methyl groups. This kind of methyl labeling ranges among the epigenetic changes that do not change the sequence of DNA building blocks. Such labels are found particularly often in genes which act as important inhibitors of pathogenic cell growth. [More]

California and Arizona researchers have identified a gene variant that carries nearly twice the risk of developing an increasingly common type of blood cancer, according to a study published online today by the science journal Nature Genetics. [More]

The development of blood from stem cell to fully formed blood cell follows a genetically determined program. When it works properly, blood formation stops when it reaches maturity. But when it doesn't, genetic mutations can prevent the stop signal and cause the developing cells to turn cancerous. In research published in Nature, Rockefeller University scientists show for the first time that a misreading of the blood cells' histone code is responsible for acute myeloid leukemia, a rare form of the deadly blood cancer. [More]

Data showing the ability of omacetaxine to kill leukemic stem cells in mouse models with drug-resistant chronic myelogenous leukemia (CML) are the subject of an advance online publication in the journal Leukemia, ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today. [More]

Testing of blood specimens may detect abnormal white blood cells in patients years before the chronic form of lymphocytic leukemia (CLL) develops, according to research published in the current issue of the New England Journal of Medicine. [More]